Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 128

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA

Howden, Benjamin P., Peleg, Anton Y., Stinear, Timothy P.·2014·Infection, Genetics and Evolution

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.meegid.2013.03.047

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 73

  1. Akins, 2001, Antimicrob. Agents Chemother., 45, 454, 10.1128/AAC.45.2.454-459.2001 · DOI · Paper page
  2. Bagnoli, 2012, Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials, Front. Cell. Infect. Microbiol., 2, 16, 10.3389/fcimb.2012.00016 · DOI · Paper page
  3. Boyle-Vavra, 2000, Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates, Antimicrob. Agents Chemother., 44, 272, 10.1128/AAC.44.2.272-277.2000 · DOI
  4. Boyle-Vavra, 2003, Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance, Antimicrob. Agents Chemother., 47, 2036, 10.1128/AAC.47.6.2036-2039.2003 · DOI
  5. Boyle-Vavra, 2011, Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure, Antimicrob. Agents Chemother., 55, 2018, 10.1128/AAC.01593-10 · DOI
  6. Cameron, 2011, The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes, Clin. Infect. Dis., 53, 576, 10.1093/cid/cir473 · DOI
  7. Cameron, 2012, Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus, J. Infect. Dis., 205, 1677, 10.1093/infdis/jis252 · DOI
  8. Chambers, 2001, The changing epidemiology of Staphylococcus aureus?, Emerg. Infect. Dis., 7, 178, 10.3201/eid0702.010204 · DOI · Paper page
  9. Charles, 2004, Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus, Clin. Infect. Dis., 38, 448, 10.1086/381093 · DOI · Paper page
  10. Cosgrove, 2004, Staphylococcus aureus with reduced susceptibility to vancomycin, Clin. Infect. Dis., 39, 539, 10.1086/422458 · DOI · Paper page
  11. Cui, 2005, DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 49, 3404, 10.1128/AAC.49.8.3404-3413.2005 · DOI
  12. Cui, 2003, Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus, J. Clin. Microbiol., 41, 5, 10.1128/JCM.41.1.5-14.2003 · DOI · Paper page
  13. Cui, 2000, Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50, Antimicrob. Agents Chemother., 44, 2276, 10.1128/AAC.44.9.2276-2285.2000 · DOI · Paper page
  14. Cui, 2009, Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 1231, 10.1128/AAC.01173-08 · DOI
  15. de Lassence, 2006, Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit, Clin. Infect. Dis., 42, 170, 10.1086/498898 · DOI
  16. Delaune, 2012, The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response, Infect. Immun., 80, 3438, 10.1128/IAI.00195-12 · DOI · Paper page
  17. Dubrac, 2008, A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway, Mol. Microbiol., 70, 1307, 10.1111/j.1365-2958.2008.06483.x · DOI · Paper page
  18. Fukushima, 2011, A role for the essential YycG sensor histidine kinase in sensing cell division, Mol. Microbiol., 79, 503, 10.1111/j.1365-2958.2010.07464.x · DOI
  19. Gao, 2013, The RpoB H481Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus, J. Infect. Dis., 207, 929, 10.1093/infdis/jis772 · DOI
  20. Gao, 2010, Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection, PLoS Pathog., 6, e1000944, 10.1371/journal.ppat.1000944 · DOI · Paper page
  21. Gardete, 2012, Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300, PLoS Pathog., 8, e1002505, 10.1371/journal.ppat.1002505 · DOI · Paper page
  22. Hafer, 2012, Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 56, 5845, 10.1128/AAC.01139-12 · DOI
  23. Hanaki, 1998, Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50, J. Antimicrob. Chemother., 42, 199, 10.1093/jac/42.2.199 · DOI · Paper page
  24. Hiramatsu, 2001, Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance, Lancet Infect. Dis., 1, 147, 10.1016/S1473-3099(01)00091-3 · DOI · Paper page
  25. Hiramatsu, 1997, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
  26. Hiramatsu, 1997, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J. Antimicrob. Chemother., 40, 135, 10.1093/jac/40.1.135 · DOI · Paper page
  27. Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrob. Agents Chemother., 53, 3447, 10.1128/AAC.01365-08 · DOI
  28. Howden, 2006, Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia, Antimicrob. Agents Chemother., 50, 3039, 10.1128/AAC.00422-06 · DOI · Paper page
  29. Howden, 2011, Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR, PLoS Pathog., 7, e1002359, 10.1371/journal.ppat.1002359 · DOI · Paper page
  30. Howden, 2008, Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia, BMC Microbiol., 8, 39, 10.1186/1471-2180-8-39 · DOI
  31. Howden, 2008, Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus, Antimicrob. Agents Chemother., 52, 3755, 10.1128/AAC.01613-07 · DOI
  32. Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin. Infect. Dis., 38, 521, 10.1086/381202 · DOI · Paper page
  33. Howe, 2004, Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages, Emerg. Infect. Dis., 10, 855, 10.3201/eid1005.030556 · DOI
  34. Jansen, 2007, Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus, Int. J. Med. Microbiol., 297, 205, 10.1016/j.ijmm.2007.02.002 · DOI · Paper page
  35. Kaatz, 1990, Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis, J. Infect. Dis., 162, 103, 10.1093/infdis/162.1.103 · DOI · Paper page
  36. Katayama, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
  37. Katayama, 2009, Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem, Antimicrob. Agents Chemother., 53, 3190, 10.1128/AAC.00834-08 · DOI
  38. Kelley, 2011, Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure, J. Antimicrob. Chemother., 66, 1057, 10.1093/jac/dkr066 · DOI
  39. Koehl, 2004, Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 48, 3749, 10.1128/AAC.48.10.3749-3757.2004 · DOI
  40. Lowy, 1998, Staphylococcus aureus infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
  41. Lowy, 2003, Antimicrobial resistance: the example of Staphylococcus aureus, J. Clin. Invest., 111, 1265, 10.1172/JCI200318535 · doi:10.1172/jci200318535 · Paper page
  42. Majcherczyk, 2008, Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis, Microb. Pathog., 45, 408, 10.1016/j.micpath.2008.09.003 · DOI
  43. Manquat, 1992, Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia, J. Antimicrob. Chemother., 29, 731, 10.1093/jac/29.6.731 · DOI
  44. Maor, 2009, Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia, J. Infect. Dis., 199, 619, 10.1086/596629 · DOI · Paper page
  45. Marco, 2008, Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 52, 2538, 10.1128/AAC.00510-07 · DOI
  46. Matsuo, 2011, Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3, Antimicrob. Agents Chemother., 55, 4188, 10.1128/AAC.00398-11 · DOI
  47. McAleese, 2006, Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin, J. Bacteriol., 188, 1120, 10.1128/JB.188.3.1120-1133.2006 · DOI · Paper page
  48. McCallum, 2006, In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance, Antimicrob. Agents Chemother., 50, 2352, 10.1128/AAC.00073-06 · DOI
  49. Moise, 2009, Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions, Lancet Infect. Dis., 9, 617, 10.1016/S1473-3099(09)70200-2 · DOI
  50. Musta, 2009, Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11years, J. Clin. Microbiol., 47, 1640, 10.1128/JCM.02135-08 · DOI
  51. Mwangi, 2007, Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing, Proc. Natl. Acad. Sci. USA, 104, 9451, 10.1073/pnas.0609839104 · DOI · Paper page
  52. Neoh, 2008, Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance, Antimicrob. Agents Chemother., 52, 45, 10.1128/AAC.00534-07 · DOI
  53. Park, 2012, Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation, J. Med. Microbiol., 61, 345, 10.1099/jmm.0.035204-0 · doi:10.1099/jmm.0.035204-0
  54. Passalacqua, 2012, A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin, Antimicrob. Agents Chemother., 56, 5212, 10.1128/AAC.05770-11 · DOI
  55. Peleg, 2009, Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection, J. Infect. Dis., 199, 532, 10.1086/596511 · DOI · Paper page
  56. Pereira, 2007, Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 51, 3627, 10.1128/AAC.00431-07 · DOI
  57. Perichon, 2009, VanA-type vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 · DOI · Paper page
  58. Pfeltz, 2000, Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds, Antimicrob. Agents Chemother., 44, 294, 10.1128/AAC.44.2.294-303.2000 · DOI
  59. Pillai, 2009, Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus, Clin. Infect. Dis., 49, 1169, 10.1086/605636 · DOI
  60. Rammelkamp, 1942, Resistance of Staphylococcus aureus to the action of penicillin, Proc. Royal Soc. Exper. Biol. Med., 51, 386, 10.3181/00379727-51-13986 · DOI · Paper page
  61. Renzoni, 2011, Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus, PLoS One, 6, e21577, 10.1371/journal.pone.0021577 · DOI
  62. Robert, 2006, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20year study in a large French teaching hospital, 1983–2002, J. Antimicrob. Chemother., 57, 506, 10.1093/jac/dki486 · DOI
  63. Rybak, 2005, Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin, Diagn. Microbiol. Infect. Dis., 51, 119, 10.1016/j.diagmicrobio.2004.09.005 · DOI
  64. Scherl, 2006, Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers, BMC Genomics, 7, 296, 10.1186/1471-2164-7-296 · DOI
  65. Shoji, 2011, WalK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 3870, 10.1128/AAC.01563-10 · DOI
  66. Sieradzki, 2003, Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus, J. Bacteriol., 185, 7103, 10.1128/JB.185.24.7103-7110.2003 · DOI · Paper page
  67. Smith, 1999, Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group, N. Engl. J. Med., 340, 493, 10.1056/NEJM199902183400701 · DOI · Paper page
  68. Tenover, 2007, The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus, Clin. Infect. Dis., 44, 1208, 10.1086/513203 · DOI · Paper page
  69. Tenover, 2009, Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy, Int. J. Antimicrob. Agents, 33, 564, 10.1016/j.ijantimicag.2008.12.010 · DOI
  70. van Hal, 2011, Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections, PLoS One, 6, e21217, 10.1371/journal.pone.0021217 · DOI
  71. van Hal, 2011, Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates, Antimicrob. Agents Chemother., 55, 405, 10.1128/AAC.01133-10 · DOI · Paper page
  72. Watanabe, 2011, Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus, J. Clin. Microbiol., 49, 2680, 10.1128/JCM.02144-10 · DOI · Paper page
  73. Yamakawa, 2012, Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study, J. Infect. Chemother., 18, 406, 10.1007/s10156-011-0330-2 · DOI

Cited by

See all 128

Metadata

Authors
Howden, B. P., Peleg, A. Y., & Stinear, T. P.
Venue
Infection, Genetics and Evolution
Publisher
Elsevier BV
Published
2014-01
Volume
21
Pages
575-582
ISSN
1567-1348
Cited by
128
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. https://app.cochat.ai/papers/10.1016/j.meegid.2013.03.047
The paper
Howden, B. P., Peleg, A. Y., & Stinear, T. P. (2014). The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infection, Genetics and Evolution. https://doi.org/10.1016/j.meegid.2013.03.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.